Evidence and support

A prescription digital therapeutic already exists

At least four-point EPDS improvement: 86.3% versus 23.9% with sham app.

Research preview · selected sources rechecked September 14, 2026 · independent clinical review pending. These editorial assessments are not formal GRADE ratings. No study here establishes an effect of Brighter Postpartum.

promising treatment · C29

A prescription digital therapeutic already exists

Population and setting: MamaLift Plus trial: 141 adults with confirmed PPD and EPDS 13–19.
What was found: At least four-point EPDS improvement: 86.3% versus 23.9% with sham app.
Limits and applicability: Not remission or prevention. Sponsor-affiliated study; FDA clearance is for prescription adjunctive clinician-managed outpatient care in adults 22+.

Sources: S43 · S44 · Evidence record ↗

Interpretation boundary

Prevention, treatment, comfort, mechanism and research status are separate questions. Read the original source and retain its population, timing and limitations. This is not a personalized recommendation or a claim that our support program has this effect.

Version 1. Independent clinical review pending. Explore the connected evidence.